针对IL17RA调节炎症反应的创新性类疗法
Xinmin Wang1, Hang Bao1, Yuya Wang2
1School of Life Science and Technology, Inner Mongolia University of Science and Technology, Baotou, 014010, China.
Scientific reports
|March 23, 2025
概括
一种新型的,AL-8(0),有效地抑制了互白素-17受体A (IL17RA) 途径,为自身免疫性疾病的单克隆抗体提供了一个有希望的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 介素-17受体A (IL17RA) 是自身免疫性疾病发病的关键调解者.
- 目前针对IL17RA的治疗方法 (单克隆抗体) 有局限性,包括成本,生产复杂性和口服生物可用性差.
研究的目的:
- 开发和评估AL-8(0),一种新的IL17A-IL17RA信号通路的抑制剂.
- 评估AL-8(0) 的结合亲和力,抗炎活性和对自身免疫性疾病的治疗潜力.
主要方法:
- 胺合成和AL-8的净化(0).
- 生物物理测定以确定与IL17RA的结合亲和力.
- 使用IL17RA表达和缺陷细胞进行细胞测试以评估抗炎活性.
主要成果:
- AL-8(0) 显示高纯度和强大的结合亲和力对IL17RA.
- 该有效地抑制了相关细胞类型的炎症性细胞因子产生.
- AL-8(0) 的抗炎作用与单克隆抗体相当,并且依赖于IL17RA表达.
结论:
- AL-8(0) 显示出作为针对IL17RA介导的自身免疫性疾病的性治疗药物的显著潜力.
- 这种在现有疗法上具有优势,包括口服的可能性和更好的可扩展性.
- 进一步开发AL-8(0) 可能会导致对炎症疾病的创新治疗方法.
相关概念视频
T Cell Types and Functions
730
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
730
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
Inflammatory Response
1.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123


